A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

Conditions

• Obesity and Cardiovascular Risk

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Oral BGE-102 — DRUG
  Capsules
• Oral Placebo Matching BGE-102 — DRUG
  Capsules

Study Details

The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health. Participants will receive either BGE-102 or placebo. This study will be checking safety and tolerability of BGE-102.

Key Dates

First listed

Jun 18, 2026

Start date

Jun 11, 2026

Status verified

Sep 2026

Primary completion

Nov 30, 2026

Completion

Dec 31, 2026

Study Design

Enrollment

160 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Arm A: BGE-102 Dose A
  capsules dosed once daily in the morning
• Experimental: Arm B: BGE-102 Dose B
  capsules dosed once daily in the morning
• Experimental: Arm C: BGE-102 Dose C
  capsules dosed once daily in the morning
• Placebo Comparator: Arm D: Dose D
  capsules dosed once daily in the morning

Primary Outcome Measure

Percent change in hsCRP (Dose A) [ Time Frame: Week 12 ]

Locations (16)